COLL · Collegium Pharmaceutical, Inc
Market Cap
$766.03M
Shares
32.56M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$780.57M
+23.6%
FY2025
Net Income
$62.87M
-9.1%
FY2025
Gross Margin
59.35%
-0.4pp
FY2025
Operating Margin
23.01%
-3.9pp
FY2025
Diluted EPS
$1.73
-7%
FY2025
Operating Cash Flow
$329.32M
+60.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $808.21M | $780.57M | $631.45M | $566.77M | $463.93M | $276.87MG | $310.02M | $296.7M | $280.41M | $28.48M | $1.71M | — | — | — | |
| $323.12M | $317.31M | $254.11M | $240.6M | $254.45M | $126.25M | $130.18M | $193.66M | $165.68M | $2.6M | $213K | — | — | — | |
| $485.09M | $463.26M | $377.34M | $326.17M | $209.49M | $150.62M | $179.84M | $103.04M | $114.74M | — | — | — | — | — | |
| — | 59.35% | 59.76% | 57.55% | 45.15% | 54.4% | 58.01% | 34.73% | 40.92% | — | — | — | — | — | |
| — | — | $0 | $0 | $3.98M | $9.45M | $9.77M | $10.34M | $8.66M | $8.57M | $14.95M | $7.98M | $14.96M | $14.16M | |
| $80.63M | — | — | — | — | — | — | — | — | — | — | $18.93M | $2.71M | $1.89M | |
| $327.69M | $284.8M | $210.36M | $159.21M | $172.19M | $118.96M | $113.83M | $116.45M | $126.76M | $92.76M | $80.63M | $18.93M | $2.71M | — | |
| — | $221.89M | $165.3M | $145.76M | — | $67.18M | $60.68M | $14.75M | $109.83M | $258K | $397K | — | — | — | |
| $785K | — | — | — | — | — | — | $731K | $1.07M | $594K | $655K | $171K | $187K | — | |
| — | — | — | — | — | $4.58M | — | — | — | — | — | — | — | — | |
| $327.65M | $283.62M | $207.45M | $159.21M | $176.17M | $132.99M | $123.6M | $126.79M | $135.42M | — | $95.79M | $26.91M | $17.67M | $16.04M | |
| — | — | — | — | — | — | — | $320.45M | $301.1M | $103.92M | $95.79M | $26.91M | — | — | |
| $157.44M | $179.64M | $169.9M | $166.96M | $33.32M | $17.63M | $56.23M | -$23.75M | -$20.69M | -$75.45M | -$94.08M | -$26.91M | -$17.67M | -$16.04M | |
| — | 23.01% | 26.91% | 29.46% | 7.18% | 6.37% | 18.14% | -8% | -7.38% | -264.95% | -5498.66% | — | — | — | |
| $39.65M | — | — | — | — | — | — | -$23.02M | -$19.61M | -$74.85M | -$93.43M | -$26.74M | -$17.48M | — | |
| $76.44M | $82.31M | $73.97M | $83.34M | $63.21M | $21.01M | $28.88M | $909K | $20.13M | — | $94K | $439K | $252K | — | |
| — | — | — | — | — | — | — | — | — | $582K | -$94K | -$348K | -$252K | -$155K | |
| $77.68M | $92.62M | $98.57M | $75.73M | -$28.85M | -$3.37M | $27.58M | -$22.72M | -$39.13M | — | — | — | — | — | |
| $29.77M | $29.75M | $29.38M | $27.58M | -$3.85M | -$74.89M | $830K | $0 | — | — | — | — | — | — | |
| $47.92M | $62.87M | $69.19M | $48.16M | -$25M | $71.52M | $26.75M | -$22.72M | -$39.13M | -$74.87M | -$94.18M | -$27.26M | -$17.92M | -$16.2M | |
| — | 8.05% | 10.96% | 8.5% | -5.39% | 25.83% | 8.63% | -7.66% | -13.95% | -262.91% | -5504.15% | — | — | — | |
| $47.58M | $63.13M | $69.23M | $48.17M | -$25M | $71.52M | — | — | — | — | — | — | — | — | |
| USD/shares | $1.53 | $1.98 | $2.14 | $1.43 | -$0.74 | $2.05 | $0.78 | -$0.68 | -$1.19 | — | -$3.88 | -$1.48 | -$22.72 | — |
| USD/shares | $1.24 | $1.73 | $1.86 | $1.29 | -$0.74 | $1.86 | $0.76 | -$0.68 | -$1.19 | — | — | — | — | — |
| shares | — | 31.71M | 32.27M | 33.74M | 33.83M | 34.94M | 34.41M | 33.45M | 32.95M | 30.27M | 24.26M | 13.54M | 934K | 1.7M |
| shares | — | 39.7M | 40.42M | 41.79M | 33.83M | 41.05M | 35.15M | 33.45M | 32.95M | 30.27M | 24.26M | 13.54M | 934K | 1.7M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2025: $222.05M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.97×
EV/EBIT
—
Peer median 17.65×
P/E (TTM)
—
Peer median 14.96×
Peer medians compare against the 50 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Single Reportable Segment | $780,567,000 | $631,449,000 | $566,767,000 | $463,933,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Belbuca | $221,653,000 | $211,269,000 | $182,095,000 | $126,461,000 | — | — | — | — |
| Xtampza ER | $199,308,000 | $191,330,000 | $177,374,000 | — | — | — | — | — |
| Jornay PM | $148,857,000 | $37,239,000 | $0 | — | — | — | — | — |
| Nucynta IR | $115,312,000 | $100,740,000 | $108,150,000 | $112,058,000 | $102,222,000 | $116,318,000 | $117,680,000 | $129,917,000 |
| Nucynta ER | $80,985,000 | $75,767,000 | $82,653,000 | $72,418,000 | $70,938,000 | $65,714,000 | $74,009,000 | $81,113,000 |
| Symproic and Other | $14,452,000 | $15,104,000 | $16,495,000 | — | — | — | — | — |
| Bema Fentany | — | — | — | $1,925,000 | — | — | — | — |
| Symproic | — | — | — | $12,267,000 | — | — | — | — |
| Xtampza | — | — | — | $138,804,000 | $103,708,000 | $127,984,000 | $105,012,000 | $69,383,000 |
Key facts
CIK
1267565
CUSIP
19459J104
13F (30d)
196 filings
195 filers
Visit website
Investor relations